KR102181893B1 - Cosmetic and pharmaceutical compositin comprising aloe extract, upland rice extract and ceramide - Google Patents

Abstract

The present invention relates to a cosmetic and pharmaceutical composition comprising a natural extract and ceramide, and more particularly, by containing a mixed composition comprising an aloe extract, a field rice extract and ceramide as an active ingredient, a skin moisturizing effect, a skin barrier strengthening effect, and It provides a cosmetic and pharmaceutical composition that can be usefully used for the prevention, improvement and treatment of skin diseases because it has excellent atopic improvement effect.

Description

Cosmetics and pharmaceutical compositions containing aloe extract, field rice extract, and ceramide {COSMETIC AND PHARMACEUTICAL COMPOSITIN COMPRISING ALOE EXTRACT, UPLAND RICE EXTRACT AND CERAMIDE}

The present invention relates to a cosmetic and pharmaceutical composition comprising a natural extract and ceramide, and more specifically, a mixed composition comprising aloe extract, field rice extract and ceramide as an active ingredient for preventing, improving and treating skin diseases It relates to cosmetics and pharmaceutical compositions that can be usefully used as.

The skin carries about 65-70% of the moisture that the human body has, that is, various physiologically active substances necessary for the human body, and helps to keep the skin soft and moist. Do it.

This skin is largely divided into three layers: epidermis, dermis, and subcutaneous fat tissue from the outside.Especially, the epidermis, located at the outermost part of the skin, blocks excessive penetration of substances from the outside, and moisture is excessive outside the body. It performs a protective function to suppress evaporation.

This protective function is possible when the stratum corneum composed of keratinocytes is normally formed and maintained.

Keratinocytes are cells that are formed through phased morphological and functional changes as the basal cells that continuously proliferate in the stratum basale move to the stratum corneum. The formation cells are eliminated from the skin, and the process of epidermis differentiation or keratinization is repeated in which new keratinocytes raised from the lowermost layer of the epidermis take over their function. In this keratinization process, keratinocytes produce high-concentration Natural Moisturizing Factor (NMF), which is a water-soluble component, and intercellular lipids such as ceramide, cholesterol, and fatty acids, and the stratum corneum acts as a barrier layer to the outside. By retaining the function as a skin barrier, the skin acts not only to show flexibility, but also to maintain adequate moisture.

However, skin dryness, which is considered one of the major diseases of the modern society, is one of the symptoms caused by abnormal skin barrier function, artificial temperature control of cooling/heating according to changes in environment or lifestyle, and various kinds of problems occurring in social life. The moisture in the stratum corneum decreases due to various causes, such as skin stress due to stress and environmental pollution, frequent cleansing according to makeup habits, and natural skin aging due to age increase, resulting in dry skin, rough surface, and loss of shine. The need for skin moisturizers is increasing because phenomena such as dull appearance occur.

In addition, atopic dermatitis, which occurs in 10% of children, is also known to be a major cause of dry skin, more fundamentally, abnormal skin barrier function.

Currently, prescription drugs such as steroids, antihistamines, and antibiotics are predominantly prescribed for atopic dermatitis, but they cause various problems such as skin weakness and hormonal abnormalities.

Accordingly, research is being conducted to treat and alleviate the symptoms of atopy that are safe for the human body from natural products, and Korean Patent Registration No. 10-1924054 discloses a composition for improving atopic dermatitis containing as an active ingredient, a novel compound stechamon isolated from the extract of blood roots. Is described, and Korean Patent Registration No. 10-0990195 includes aroma essential oils (one or more of aroma essential oils extract, bellflower extract, lavender, tea tree, blue chamomile, white chamomile, frankincense, and sandalwood) and hyaluronic acid. , Atopic skin disease relief natural cosmetic composition is disclosed.

However, atopic dermatitis has a difference in its symptoms depending on the concentration, quantity, or activity of chemokines, and it can be seen as a phenomenon in which the proliferation of keratinocytes occurs abnormally due to immunological factors. It occurs as a complex factor between factors, and there is a limitation in finding the root and treating it.

Korean Patent Registration No. 10-1924054 Korean Patent Registration No. 10-0990195

The present invention is to solve the above problems, by containing a mixed composition containing aloe extract, field rice extract and ceramide as an active ingredient, cosmetics and pharmaceuticals that can be usefully used for the prevention, improvement and treatment of skin diseases It is an object to provide a composition.

According to an aspect of the present invention, it provides a cosmetic composition comprising a mixed composition comprising an aloe extract, a field rice extract, and ceramide as an active ingredient.

The mixed composition may provide a cosmetic composition comprising 20 to 300 parts by weight of the field rice extract based on 100 parts by weight of the aloe extract.

The mixed composition may provide a cosmetic composition comprising 20 to 300 parts by weight of the ceramide based on 100 parts by weight of the aloe extract.

The mixed composition may provide a cosmetic composition, characterized in that it further comprises 30 to 200 parts by weight of the mother and child half extract based on 100 parts by weight of the aloe extract.

It is possible to provide a cosmetic composition, characterized in that the ceramide is a similar ceramide.

The pseudo ceramide can provide a cosmetic composition, characterized in that one of the following compounds.

[Compound 1]

[Compound 2]

[Compound 3]

The cosmetic composition may provide a cosmetic composition, characterized in that for moisturizing the skin, strengthening the skin barrier, or improving atopy.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing, improving, or treating atopy, containing a mixed composition comprising an aloe extract, a field rice extract, and ceramide as an active ingredient.

The mixed composition may provide a pharmaceutical composition for preventing, improving, or treating atopy, characterized in that it further comprises a mother and baby extract.

According to the cosmetic and pharmaceutical composition containing a mixed composition containing aloe extract, rice field extract and ceramide according to the present invention, the skin moisturizing effect, skin barrier strengthening effect and atopy improvement effect are excellent, so that the prevention, improvement and treatment of skin diseases It can be useful for use.

Hereinafter, an embodiment of the present invention will be described in detail. However, this is presented as an example, and the present invention is not limited thereby, and the present invention is only defined by the scope of the claims to be described later.

In describing the present invention, when it is determined that a detailed description of a related known configuration or function may obscure the subject matter of the present invention, a detailed description thereof will be omitted.

In describing the constituent elements of the present invention, terms such as first, second, A, B, (a), and (b) may be used. These terms are only used to distinguish the component from other components, and the nature, order, or order of the component is not limited by the term.

In describing the present invention, the terms'about','substantially','degree', etc. of degree are used in or close to the numerical value when manufacturing and material tolerances specific to the stated meaning are presented. , In order to aid the understanding of the present invention, accurate or absolute numerical values are used to prevent unscrupulous infringers from unfairly using the stated disclosure.

In the present invention, the extract includes all extracts, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and their dilutions, concentrates, or dried products.

In the present invention, the term'prevention','improvement' or'treatment' refers to suppression, alleviation or elimination of the appearance or development of one or more symptoms related to a disease or disease.

The cosmetic composition according to an embodiment of the present invention may contain a mixed composition comprising an aloe extract, a field rice extract, and ceramide.

Aloe is a succulent perennial herb used today as a worldwide medicinal plant. It is similar in appearance to a cactus, but actually belongs to the lily family and aloe genus. It occupies about a tenth of the family. Originating from Africa's warm and dry climate, aloe was used by ancient Egyptians to treat skin wounds, burns, and inflammation. In the early 1930s, aloe was frequently used in hospitals for the treatment of mild skin diseases and radiation dermatitis. Since the Greek era when medicine was not developed, it has been loved by many for wound healing and has been used for a long time as a skin beauty material.

Aloe is somewhat different depending on the type, but it has a spear-like shape, has thorns on both ends of the green leaf, and the tip of the leaf is sharp. The main components of aloe are high molecular polysaccharides including hexose, aloetin, aloe ulcin, and alomitin, and most of these components are present in the gel inside the leaves.

Aloe is widely known as a plant that supplies moisture to the skin. In particular, it has an excellent skin moisturizing effect, making it a moisture barrier on the soft baby's skin. In addition, it exhibits excellent effects on wound healing and cell regeneration, and aloetin, which is the main ingredient, is effective in sterilizing the skin, thus exhibiting excellent effects in preventing skin troubles.

The aloe extract can be obtained using water, ethanol, or a mixture of water and ethanol as an extraction solvent, and the aloe is dried and pulverized to obtain a mixture of purified water and 30 to 70% ethanol as an extraction solvent.

Upland rice is rice grown in a field, and unlike paddy rice grown in watered rice fields during the entire growth period, it grows well in an unwatered field and withstands drought. Reports on paddy rice and paddy rice intervened in the Rural Development Administration describe the differences between paddy and paddy rice in various ways. Among them, to briefly explain the difference between paddy rice and paddy rice, when compared to paddy rice, paddy rice has a slightly thicker leaf and fewer pores, making the opening and closing function more sensitive than paddy rice. These thick and large ones have the advantage of high water storage capacity, and the thick and deep roots, as well as the thick stem and large size of the water tube, are described as being related to their own water supply ability.

In addition, it is described that the field rice has stronger resistance to potassium chlorate (KClO ₃ ) than the paddy rice, and the strong drought-tolerance power in young seedlings among the field rice varieties is strong because of its strong resistance to potassium chlorate. In other words, as there are various differences between field rice and paddy rice due to breeding dogs, there is a difference in moisturizing effect for them. Meanwhile, the field rice may be grown and harvested in Jeju Island, but is not limited or limited thereto.

The field rice extract may be obtained by extracting from one or more sites among outposts, roots, leaves, stems, and junggyeong.

The field rice extract can be obtained using water, ethanol, or a mixture of water and ethanol as an extraction solvent, and the field rice can be dried and pulverized to obtain a mixture of purified water and 30 to 70% ethanol as an extraction solvent.

The mixed composition may include 20 to 300 parts by weight of the field rice extract, and preferably 50 to 200 parts by weight, based on 100 parts by weight of the aloe extract. In the mixed composition, if the field rice extract is less than 20 parts by weight with respect to 100 parts by weight of the aloe extract, there may be a problem of insignificant efficacy and effect, and if it exceeds 300 parts by weight, it is economical because it is inefficient in enhancing the efficacy and effect compared to the amount used. There may be a problem.

Ceramide is a major lipid component constituting the stratum corneum, and plays an important role in the formation of skin moisturizing ability and the occurrence of skin barrier diseases. Ceramide is a type of sphingo lipid that has a structure in which fatty acids are linked to sphingosine or phytosphingosine.Ceramide accounts for about 40-50% or more of lipids between keratinocytes that make up the stratum corneum of the skin, and is essential to show the structure or function of the stratum corneum. As a component, it acts as a lipid barrier that inhibits water evaporation in the stratum corneum and functions to maintain the orderly structure of the stratum corneum. Ceramides present in the human body are classified into 6 types according to the degree of polarity. Ceramide EP (Ceramide 1), Ceramide NS, and Ceramide ENG (Ceramide 2) have the lowest polarity and have sphingosine as their skeleton, and Ceramide NP (Ceramide 3) is a synthetic N-acetylated phytosphingosine that has mainly an eryth structure. to be. Due to each of these characteristic structures and physicochemical properties, ceramide plays a role in forming an optimal transmission barrier.

In the present invention, as ceramide, the above-described ceramide may be used, and similar ceramide may be used.

The pseudo ceramide may be one of the following compounds, but is not limited thereto.

[Compound 1]

[Compound 2]

[Compound 3]

The mixed composition may include 20 to 300 parts by weight of the ceramide based on 100 parts by weight of the aloe extract, and preferably 50 to 200 parts by weight. In the mixed composition, when the ceramide is less than 20 parts by weight with respect to 100 parts by weight of the aloe extract, there may be a problem of insignificant efficacy and effect, and when it exceeds 300 parts by weight, it is inefficient in enhancing the efficacy and effect compared to the amount used, which is an economic problem. There may be.

The mixed composition containing the aloe extract, the field rice extract, and ceramide may further include a mother and child extract.

Sargassum fulvellum has a distinct distinction between roots, stems, and leaves in appearance, and its roots are stalk-shaped and grow 1 to 3m or more with one central branch. The stem is triangular or triangular and twisted. The leaves are curved from the stem toward the base, and have a spatula shape or oval shape, and a middle rib is formed to the center of the leaf. The upper leaf is lancet-shaped, and there are serrated projections on the edge, and air bubbles form from the stem on the whole body. It has a dark yellowish brown color and can be found on all coasts of Korea.

The main ingredients are alginic acid, chlorophyll a, c, β-carotene, fucoxanthin, laminarin, and mannitol. The amount of fiber and fat is very low, but when analyzed in powder form, the amount of dietary fiber and fat is more than 30%.

Mosaic half contains relatively more dietary fiber than sugar. In Korea, many kinds of chinensis are usually edible, and they are used as raw materials for seaweed industry such as alginic acid or as fertilizer. It is said that alginic acid is good for constipation and is effective in preventing colon cancer because it helps digestion of the stomach and helps intestinal movement. It is good for high blood pressure and osteoporosis due to its high mineral content, and good for thyroid dysfunction due to its high iodine content.

The Mojaban extract can be obtained using water, ethanol, or a mixture of water and ethanol as an extraction solvent, and the Mojaban is dried and pulverized to obtain a mixture of purified water and 30 to 70% ethanol as an extraction solvent.

The mixed composition may include 30 to 200 parts by weight of the mother and child and half extract based on 100 parts by weight of the aloe extract, and preferably 50 to 100 parts by weight. In the mixed composition, when the amount of the mother and child half extract is less than 30 parts by weight with respect to 100 parts by weight of the aloe extract, there may be a problem of insignificant efficacy and effect, and when it exceeds 200 parts by weight, it is economical because it is inefficient in enhancing the efficacy and effect compared to the amount used. There may be a problem.

In the present invention, the mixed composition includes all of a mixture comprising an aloe extract, a field rice extract, and a ceramide, and a mixture further comprising a mother and child half extract in the mixture.

In the present invention, the cosmetic composition containing the mixed composition as an active ingredient may be used for moisturizing the skin, strengthening the skin barrier, or improving atopy.

The skin moisturizing refers to an effect of suppressing moisture loss and supplying moisture to the skin so that moisture from the skin does not disappear quickly and stays on the skin for a long time.

The strengthening of the skin barrier refers to strengthening the barrier function of the stratum corneum located at the outermost part of the skin. The stratum corneum, the primary barrier of the skin, can be damaged by physical irritation or wounds, and in the case of atopic dermatitis or dry skin, the skin barrier of the stratum corneum does not function properly or is damaged. To treat or reduce damage to atopy or dry skin, so-called moisturizers are applied, but general moisturizers cannot solve the underlying problem by simply replenishing moisture or covering the skin. Therefore, in this aspect, the mixed composition strengthens the skin barrier function by solving the fundamental problem by increasing the expression of factors related to the barrier function of the stratum corneum.

In the present invention, the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. This is all formulations suitable for topical application, for example, lotions, emulsions, gels, creams, lotions, essences, foams, packs, soaps, ointments, sprays, and may be formulated as one selected from the group consisting of sprays and powders. It is not.

In the present invention, the cosmetic composition may include ingredients commonly used in cosmetic compositions in addition to the mixed composition. For example, fatty substances, organic solvents, solubilizing agents, thickening agents, gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, Cosmetics or skin, such as fillers, sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics It may contain adjuvants commonly used in the scientific field. The adjuvant is introduced in an amount generally used in the field of cosmetics or dermatology.

In the present invention, the active ingredient of the mixed composition is 0.001 to 50% by weight, preferably 0.05 to 20% by weight, and preferably 0.1 to 10% by weight, based on the total cosmetic composition. When the weight of the mixed composition is less than 0.001% by weight, there may be a slight problem in efficacy and effect, and when it exceeds 50% by weight, there may be problems in skin stability or formulation.

The pharmaceutical composition according to another embodiment of the present invention may include the mixed composition as an active ingredient. The pharmaceutical composition may be used for prevention, improvement or treatment of atopy. The pharmaceutical composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydrating agents or emulsifying accelerators, salts and/or buffers for controlling osmotic pressure, and other therapeutically useful substances. The pharmaceutical composition may be formulated as a lotion, cream, ointment, or gel, but is not limited thereto.

In the present invention, the active ingredient of the mixed composition is 0.001 to 50% by weight, preferably 0.05 to 20% by weight, and preferably 0.1 to 10% by weight based on the total pharmaceutical composition. When the weight of the mixed composition is less than 0.001% by weight, there may be a slight problem in efficacy and effect, and when it exceeds 50% by weight, there may be problems in skin stability or formulation.

Hereinafter, the present invention will be further described through manufacturing examples and test examples. These examples are for explaining the present invention more specifically, and the scope of the present invention is not limited to these examples.

[ Example ]

[ Manufacturing example ]

[Production Example 1] Preparation of individual extracts

Aloe, Jeju field rice, and Mocha were each washed with distilled water, dried, and pulverized with a blender to obtain a fine powder sample. To prepare each extract, a solvent in which purified water and ethanol were mixed at 5:5 was added in an amount of about 10 times that of each fine powder sample, and then extraction was performed twice. After performing the above extraction, it was filtered through a 400 mesh filter cloth, and the obtained filtrate was concentrated using a vacuum concentrator to obtain an individual extracted powder.

[Production Example 2] Preparation of Compound 3

0.9 g of sullinol and 2 ml of triethylamine were added to the reaction flask, 3 ml of methanol and 20 ml of dichloromethane were added, and the temperature was lowered at low temperature (about 5° C.). A solution of α-linolenic acid chloride (3.0 g) and dichloromethane (20 ml) was added dropwise to the reaction flask. The reaction solution was stirred at room temperature for 6 hours, and then the solution was vacuum-concentrated. The concentrated solution was dissolved in dichloromethane (30ml) and washed with 0.5N hydrochloric acid aqueous solution, saturated sodium hydrogencarbonate aqueous solution, and water. The organic solution layer was dried over anhydrous magnesium sulfate, filtered, and the solution was concentrated under reduced pressure and then recrystallized to obtain 2.9 g (82%) of a pale yellow solid yellow solid.

¹ H NMR (400MHz, DMSO-d ₆ ) δ 7.41 (d, J = 8 Hz, 1H), 5.36-5.30 (m, 6H), 4.57-4.54 (m, 2H), 3.70-3.69 (m, 1H) , 3.38-3.32 (m, 4H), 2.79-2.37 (m, 4H), 2.08-2.02 (m, 6H), 1.48-1.45 (m, 2H), 1.30-1.26 (m, 6H), 0.93 (t, J = 7.6 Hz, 3H).; ¹³ C NMR (100 MHz, CDCl ₃ ) δ 172.53, 131.95, 130.37, 130.19, 128.39, 128.38, 128.20, 128.00, 127.44, 60.67, 53.18, 35.88, 31.36, 29.51, 29.18, 29.14, 29.06, 27.11, 27.06, 25.79, 25.66, 25.57, 22.44, 20.50, 14.58, 14.39.; FT-IR (Neat) 3300 cm -1, 2928 cm -1, 2853 cm -1, 1641 cm -1, 1548 cm -1, 1467cm -1, 1424 cm -1, 1387 cm -1, 1248 cm -1, 1073 cm ^-1 , 1058 cm ^-1 .; MS (ESI): m/z = 374.27 [M+Na] ⁺ .

[Production Example 3] Preparation of the composition

Compositions according to Examples and Comparative Examples were prepared in the composition shown in Table 1 below using the aloe extract prepared according to Preparation Example 1, the Jeju field rice extract, and the mother-and-law extract and Compound 3 synthesized according to Preparation Example 2.

Aloe
extract Paddy
extract Half hat
extract Ceramide 2(NG) Ceramide 3(NP) Compound 3 Untreated group - - - - - - Comparative Example 1 One - - - - - Comparative Example 2 - One - - - - Comparative Example 3 - - - - - One Comparative Example 4 - - One - - - Comparative Example 5 One One - - - - Comparative Example 6 One One One - - - Example 1 One One - One - - Example 2 One 2 - - One - Example 3 One One - - - One Example 4 One One - - - 2 Example 5 One One One - - 0.5 Example 6 One 0.5 0.5 - - 2 Example 7 One One One - - One

(Unit: parts by weight)

[ Test example ]

[Test Example 1] Skin keratinocyte culture

HaCaT cells, which are skin keratinocytes, are Dr. Pre-sale from CG Hyun (Jeju National University, Korea) using Dulbecco's Modified Eagle's Medium (DMEM) medium containing 100 units/ml penicillin-streptomycin and 10% fetal bovine serum (FBS) at 37℃, 5% CO ₂ And subcultured at intervals of 3 to 4 days.

[Test Example 2] Cytotoxicity evaluation (EZ-cytox assay)

The EZ-cytox assay is a representative method of measuring cell viability by using the principle that water solution tetrazolium salt (WST) reacts with dehydrogenase of living cells to produce orange water-soluble formazan.

In order to check the toxicity in skin keratinocytes, HaCaT cells were dispensed into a 96 well plate at 5 Х 10 ⁴ cells/mL using DMEM medium added with 10% FBS, and under 37℃, 5% CO ₂ conditions for 18 hours. During incubation. The cultured HaCaT cells were exchanged with serum-free DMEM to treat the extract to be evaluated. Thereafter, EZ-cytox was added to each well and reacted for 30 minutes at 37°C and 5% CO ₂ conditions, and then absorbance was measured at 450 nm using a microplate reader. The average absorbance value for each sample group was obtained, and the cell viability was evaluated by comparing it with the absorbance value of the control group.

division Treatment concentration (μg/mL) Cytotoxicity HaCaT cell viability (%) Untreated group - 100 Comparative Example 1 100 103 ± 2.1 Comparative Example 2 100 101 ± 1.2 Comparative Example 3 100 103 ± 1.3 Comparative Example 4 100 101 ± 2.4 Comparative Example 5 100 101 ± 4.1 Comparative Example 6 100 101 ± 1.1 Example 1 100 104 ± 1.1 Example 2 100 105 ± 3.2 Example 3 100 101 ± 4.1 Example 4 100 100 ± 1.3 Example 5 100 102 ± 2.2 Example 6 100 103 ± 3.1 Example 7 100 103 ± 4.3

As shown in Table 2, both of Comparative Examples 1 to 6 and Examples 1 to 7, which are compositions containing ceramides according to the present invention, did not show cytotoxicity in skin keratinocytes and macrophages.

[Test Example 3] Moisturizing effect

[Test Example 3-1] Confirmation of the effect of increasing the production amount of hyaluronic acid, a moisturizing factor

HaCaT cells were dispensed to a 24 well plate at 1.0 Х 10 ⁵ cells/mL and cultured for 18 hours at 37°C and 5% CO ₂ . Serum-free DMEM was exchanged, and the composition prepared according to Table 1 was treated and incubated for 24 hours. Thereafter, the culture medium was removed, centrifuged at 15,000 rpm for 5 minutes, and the supernatant was removed and stored frozen (-20°C) until quantification. The enzyme immunoassay (ELISA: Enzyme-Linked Immunosorbent Assay) was performed using a hyaluronic acid ELISA kit (Elabscience Biotechnology Co., Ltd.) and was carried out by the method provided by the manufacturer.

Treatment concentration (μg/mL) Hyaluronic Acid production (%) Untreated group - 100 Comparative Example 1 100 181 ± 2.8 Comparative Example 2 100 120 ± 2.1 Comparative Example 3 100 165 ± 5.6 Comparative Example 4 100 130 ± 3.6 Comparative Example 5 100 201 ± 6.1 Comparative Example 6 100 215 ± 2.6 Example 1 100 222 ± 2.2 Example 2 100 226 ± 5.9 Example 3 100 231 ± 6.1 Example 4 100 236 ± 3.3 Example 5 100 248 ± 1.7 Example 6 100 261 ± 4.2 Example 7 100 252 ± 2.2 Retinoic acid 10 243 ± 0.6

As shown in Table 3, the amount of hyaluronic acid produced as a skin moisturizing factor was higher in the case of treating Examples 1 to 7, which are compositions containing ceramides according to the present invention, than Comparative Examples 1 to 6. In particular, the compositions of Examples 5 to 7 including the aloe extract, Jeju field rice extract, the complex extract including the maternal and ceramide extract and the ceramide produced hyaluronic acid of 248% or more, which is higher than the control retinoic acid.

[Test Example 3-2] Confirmation of the effect of increasing the amount of moisturizing factor Aquaporin3 (AQP3) production

HaCaT cells were aliquoted into a 6 well plate at 4.0 Х 10 ⁵ cells/mL and cultured for 18 hours at 37°C and 5% CO ₂ . Serum-free DMEM was exchanged, and the composition prepared according to Table 1 was treated and cultured for 24 hours. Subsequently, the culture medium was removed for each group and washed with PBS, followed by treatment with PBS containing no drugs that may affect protein quantification. The cells were lysed by repeating incubation at low and room temperature, and then proteins were collected. Quantification was performed using the AQP3-ELISA kit (Elabscience Biotechnology Co., Ltd) and was performed by the method provided by the manufacturer.

Treatment concentration (μg/mL) Aquaporin3 production (%) Untreated group - 100 Comparative Example 1 100 172 ± 5.4 Comparative Example 2 100 135 ± 4.8 Comparative Example 3 100 138 ± 4.3 Comparative Example 4 100 129 ± 3.1 Comparative Example 5 100 192 ± 4.1 Comparative Example 6 100 205 ± 4.5 Example 1 100 236 ± 4.2 Example 2 100 242 ± 6.2 Example 3 100 258 ± 4.2 Example 4 100 272 ± 2.9 Example 5 100 249 ± 2.6 Example 6 100 289 ± 3.3 Example 7 100 271 ± 4.8 Retinoic acid 10 234 ± 3.9

As shown in Table 4, the production amount of Aquaporin3, which is a skin moisturizing factor, was higher in the case of treating Examples 1 to 7, which are compositions containing ceramides of the present invention, than in Comparative Examples 1 to 6. In addition, looking at Comparative Examples 1 to 3, which are individual extracts, aloe was the highest, and it can be seen that the mother and child half appeared higher than other extracts. In addition, looking at Comparative Examples 1, 5, and 6, it seems to enhance the effect when the field rice is included rather than a single aloe extract, and it was confirmed that the production amount of Aquaporin3 was further increased when the mother and the baby were added thereto. Looking at Comparative Example 6 and Example 1, it can be seen that the case of including more ceramide than the mother and child half extract in the complex extract of aloe and paddy rice, which causes the effect to be enhanced, exhibits much superior efficacy. Tables 3 and 4 above. It was confirmed that the aloe and field rice complex extract containing ceramide of the present invention has the effect of remarkably enhancing the production rate of hyaluronic acid and Aquaporin 3 and thus is very effective in moisturizing the skin.

[Test Example 4] Strengthening the skin barrier

[Test Example 4-1] Related Test 1

HaCaT cells were aliquoted into a 6 well plate at 4.0 Х 10 ⁵ cells/mL and cultured for 18 hours at 37°C and 5% CO ₂ . Serum-free DMEM was exchanged, and the composition prepared according to Table 1 was treated and cultured for 24 hours. Subsequently, the culture medium was removed for each group and washed with PBS, followed by treatment with PBS containing no drugs that may affect protein quantification. The cells were lysed by repeating incubation at low and room temperature, and then proteins were collected. Quantification was performed using a Filaggrin-ELISA kit (Elabscience Biotechnology Co., Ltd) and was performed by a method provided by the manufacturer.

Treatment concentration (μg/mL) Filaggrin production (%) Untreated group - 100 Comparative Example 1 100 169 ± 4.9 Comparative Example 2 100 121 ± 3.4 Comparative Example 3 100 177 ± 2.7 Comparative Example 4 100 119 ± 7.1 Comparative Example 5 100 178 ± 5.5 Comparative Example 6 100 182 ± 3.3 Example 1 100 196 ± 2.4 Example 2 100 190 ± 1.8 Example 3 100 201 ± 5.5 Example 4 100 206 ± 6.3 Example 5 100 215 ± 3.9 Example 6 100 259 ± 4.6 Example 7 100 252 ± 5.1 Retinoic acid 10 217 ± 3.8

As shown in Table 5, in the case of treatment of Examples 1 to 7, which are compositions containing ceramide of the present invention, rather than Comparative Examples 1 to 6, the expression of filaggrin is promoted to prevent skin dryness and It can be seen that it prevents damage to the skin barrier and can quickly improve the damaged skin barrier.

[Test Example 4-2] Related Test 2

HaCaT cells were aliquoted into a 6 well plate at 4.0 Х 10 ⁵ cells/mL, and cultured for 18 hours at 37°C and 5% CO ₂ . Serum-free DMEM was exchanged, and the composition prepared according to Table 1 was treated and incubated for 24 hours. After removing the culture medium for each group and washing with PBS, PBS containing no drugs that may affect protein quantification was treated. The cells were lysed by repeating incubation at low and room temperature, and then proteins were collected. Quantification was performed using an Involucrin-ELISA kit (Elabscience Biotechnology Co., Ltd.) and was performed by a method provided by the manufacturer.

Treatment concentration (μg/mL) Involucrin production (%) Untreated group - 100 Comparative Example 1 100 181 ± 3.5 Comparative Example 2 100 131 ± 1.2 Comparative Example 3 100 159 ± 3.8 Comparative Example 4 100 119 ± 2.1 Comparative Example 5 100 185 ± 5.2 Comparative Example 6 100 189 ± 7.6 Example 1 100 196 ± 2.4 Example 2 100 203 ± 7.8 Example 3 100 195 ± 5.2 Example 4 100 199 ± 3.1 Example 5 100 232 ± 6.1 Example 6 100 254 ± 4.4 Example 7 100 247 ± 2.8 Retinoic acid 10 228 ± 1.7

As shown in Table 6, in the case of treatment of Examples 1 to 7, which are compositions containing ceramides of the present invention, rather than Comparative Examples 1 to 6, the expression of involucrin was promoted to prevent skin dryness and ultraviolet rays. It can be seen that damage to the skin barrier caused by is prevented and the damaged skin barrier can be quickly improved.

[Test Example 5] Measurement of TARC and MDC production inhibitory activity as atopic factors

In order to confirm the atopic improvement effect on the composition of the present invention, it was attempted to analyze the activity of inhibiting the production of atopic chemokine (TARC: Thymus and activation regulated chemokine, MDC: Macrophage-derived chemokine).

HaCaT cells were dispensed to a 24 well plate at 1.0 Х 10 ⁵ cells/mL and cultured for 18 hours at 37°C and 5% CO ₂ . Serum-free DMEM was exchanged, and the composition prepared according to Table 1 and interferon-γ (IFN-γ, 10 ng/mL) were treated together and incubated for a certain time. Thereafter, the culture medium was centrifuged (12,000 rpm, 3 min) to measure the atopic chemokine production content of the obtained supernatant. All samples were stored frozen (-20°C) until quantification. TARC and MDC contents were measured using a human enzyme-linked immnunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA), and the r ² value of the standard curve for the standard was 0.99 or higher.

Treatment concentration (μg/mL) TARC generation inhibition (%) MDC generation inhibition (%) Comparative Example 1 100 13.8 ± 1.9 12.2 ± 2.6 Comparative Example 2 100 ND ND Comparative Example 3 100 21 ± 2.9 25.2 ± 5.3 Comparative Example 4 100 ND ND Comparative Example 5 100 19 ± 2.2 17.9 ± 6.2 Comparative Example 6 100 26.4 ± 7.6 24.9 ± 0.9 Example 1 100 35.3 ± 5.2 38.2 ± 6.1 Example 2 100 38.3 ± 4.8 40.2 ± 8.6 Example 3 100 45.1 ± 2.2 42.1 ± 6.2 Example 4 100 49.9 ± 1.8 45.1 ± 4.3 Example 5 100 51.8 ± 3.0 48.7 ± 5.4 Example 6 100 58.1 ± 5.2 54.2 ± 7.4 Example 7 100 55.8 ± 4.7 53.3 ± 2.1 silymarin 10 52.3 ± 1.9 40.2 ± 2.6

As shown in Table 7, Examples 1 to 7, which are compositions containing ceramides of the present invention, exhibited higher inhibition rate of atopic chemokine production than Comparative Examples 1 to 4. In particular, Comparative Examples 2 and 4 had no inhibition rate of atopic chemokine production, but as in Comparative Examples 5 and 6, in the case of the complex extract of aloe and paddy rice, the complex extract of aloe and paddy rice, and mother and baby, the inhibition rate of chemokine production was rather increased. I was able to confirm what to do. And, it was confirmed through Examples 1 to 7 that ceramide has the effect of further enhancing the efficacy of the complex extract of aloe and field rice, which was very effective in atopic skin diseases.

Formulation example

[Formulation Example 1] Preparation of flexible lotion

As shown in Table 8 below, a flexible lotion containing the composition of the present invention as an active ingredient was prepared according to a conventional method.

Ingredients Content (% by weight) Example 1 0.5 Butylene glycol 2.0 Propylene glycol 2.0 Acrylate/C10-C30 Alkylacrylate Crosspolymer 0.1 Polysorbate 80 0.4 Arginic acid 0.1 Xanthan gum 0.1 Hyaluronic acid 1.0 Preservatives, colors, flavors Appropriate amount Purified water Up to 100

[Formulation Example 2] Cream preparation

As shown in Table 9 below, a cream containing the composition of the present invention as an active ingredient was prepared according to a conventional method.

Ingredients Content (% by weight) Example 3 0.5 Beta-1,3-glucan 5.0 Polysorbate 80 1.5 Squalane 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Cetearyl olivate/ Sorbitan olivate 1.0 Preservatives, colors, flavors Appropriate amount Purified water Up to 100

[Formulation Example 3] External preparation for skin

As shown in Table 10 below, an external preparation for skin containing the composition of the present invention as an active ingredient was prepared according to a conventional method.

Ingredients Content (% by weight) Example 7 0.5 Beta-1,3-glucan 5.0 Polysorbate 80 5.0 PEG 60 2.0 Shea Butter 5.0 Squalane 5.0 glycerin 10.0 Propylene glycol 10.0 Cetearyl olivate/ Sorbitan olivate 1.0 Preservatives, colors, flavors Appropriate amount Purified water Up to 100

The above description is merely illustrative of the present invention, and those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form within the scope not departing from the essential characteristics of the present invention. I will be able to. Therefore, the disclosed embodiments and experimental examples should be considered from a descriptive point of view rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the above description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

Claims (9)

A cosmetic composition comprising a mixed composition comprising an aloe extract, a field rice extract, a ceramide and a mother and child extract,
The mixed composition comprises 0.5 to 1 parts by weight of the field rice extract, 1 to 2 parts by weight of the ceramide, and 0.5 to 1 parts by weight of the mother and child half extract based on 1 part by weight of the aloe extract. Cosmetic composition for use or atopy improvement. delete delete delete The method of claim 1,
Cosmetic composition, characterized in that the ceramide is a similar ceramide. The method of claim 5,
The cosmetic composition, characterized in that the pseudo ceramide is one of the following compounds:
[Compound 1]

[Compound 2]

[Compound 3]

. delete As a pharmaceutical composition containing as an active ingredient a mixed composition comprising an aloe extract, a field rice extract, a ceramide and a mother and child extract,
The mixed composition comprises 0.5 to 1 parts by weight of the field rice extract, 1 to 2 parts by weight of the ceramide, and 0.5 to 1 parts by weight of the mother and child half extract based on 1 part by weight of the aloe extract.Atopy prevention, improvement, or treatment Pharmaceutical composition for use. delete